Insight

Richard Sullivan: How NHS adapted Systemic Anti-Cancer Treatments for solid cancers

Photo of Richard Sullivan taken from LinkedIn

Sep 17, 2024, 10:07

Richard Sullivan: How NHS adapted Systemic Anti-Cancer Treatments for solid cancers

Richard Sullivan shared a post on X:

“We are still learning from COVID-19 pandemic. A deep analysis of how NHS adapted SACT for solid cancers and the underlying evidence base for these changes.”

Efficacy and safety of interim oncology treatments introduced for solid cancers during the COVID-19 pandemic in England: a retrospective evidence-based analysis

Authors: Mark P. Lythgoe, Alica-Joana Emhardt, Huseyin Naci, Jonathan Krell, Richard Sullivan and Ajay Aggarwal.

Source: Richard Sullivan/X

Richard Sullivan is a Professor of Cancer and Global Health at King’s College London, where he directs the King’s Institute of Cancer Policy and co-directs the Conflict and Health Research Group. His research spans from global cancer studies to conflict and health, with a focus on capacity building in conflict zones, humanitarian medicine, women’s health, and digital innovation in surgery.

Ajay Aggarwal Alica-Joana Emhardt American Society of Clinical Oncology ASCO cancer cancer awareness Cancer Policy COVID-19 COVID-19 pandemic COVID-19 response fight against cancer Global fight against cancer Huseyin Naci Jonathan Krell King’s Institute of Cancer Policy Lancet Mark P. Lythgoe National Health Service NHS OncoDaily Oncology Richard Sullivan SACT Systemic Anti-Cancer Treatments

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage